130 related articles for article (PubMed ID: 9163067)
1. Hemostatic abnormalities in inflammatory bowel disease.
Chiarantini E; Valanzano R; Liotta AA; Cellai AP; Fedi S; Ilari I; Prisco D; Tonelli F; Abbate R
Thromb Res; 1996 Apr; 82(2):137-46. PubMed ID: 9163067
[TBL] [Abstract][Full Text] [Related]
2. Persistence of hemostatic alterations in patients affected by Crohn's disease after bowel surgery.
Chiarantini E; Valanzano R; Liotta AA; Cellai AP; Ilari I; Prisco D; Antonucci E; Tonelli F; Abbate R
Thromb Res; 1997 Sep; 87(6):539-46. PubMed ID: 9330436
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease.
Weber P; Husemann S; Vielhaber H; Zimmer KP; Nowak-Göttl U
J Pediatr Gastroenterol Nutr; 1999 Apr; 28(4):418-22. PubMed ID: 10204507
[TBL] [Abstract][Full Text] [Related]
5. Determination of prothrombin activation fragments in young patients with inflammatory bowel disease.
Smith CJ; Haire WD; Kaufman SS; Mack DR
Am J Gastroenterol; 1996 Jun; 91(6):1221-5. PubMed ID: 8651175
[TBL] [Abstract][Full Text] [Related]
6. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol.
Szakács Z; Csiszár B; Kenyeres P; Sarlós P; Erőss B; Hussain A; Nagy Á; Kőszegi B; Veczák I; Farkas N; Bódis E; Márta K; Szentesi A; Tőkés-Füzesi M; Berki T; Vincze Á; Tóth K; Hegyi P; Bajor J
BMJ Open; 2019 Mar; 9(3):e026315. PubMed ID: 30904871
[TBL] [Abstract][Full Text] [Related]
7. Antiphospholipid antibodies in inflammatory bowel diseases.
Martinović Z; Perisić K; Pejnović N; Lukacević S; Rabrenović L; Petrović M
Vojnosanit Pregl; 1998; 55(2 Suppl):47-9. PubMed ID: 9623359
[TBL] [Abstract][Full Text] [Related]
8. Antiphospholipid Antibodies and Procoagulant Profile in Tunisians With Inflammatory Bowel Diseases.
Kraiem I; Hadhri S; Ben Rejeb M; Ifa L; Jmaa A; Ajmi S; Skouri H
Clin Appl Thromb Hemost; 2016 Nov; 22(8):734-742. PubMed ID: 25878173
[TBL] [Abstract][Full Text] [Related]
9. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease.
Koutroubakis IE; Theodoropoulou A; Xidakis C; Sfiridaki A; Notas G; Kolios G; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1147-52. PubMed ID: 15489574
[TBL] [Abstract][Full Text] [Related]
10. Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.
Owczarek D; Undas A; Foley JH; Nesheim ME; Jabłonski K; Mach T
J Crohns Colitis; 2012 Feb; 6(1):13-20. PubMed ID: 22261523
[TBL] [Abstract][Full Text] [Related]
11. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease.
Souto JC; Martínez E; Roca M; Mateo J; Pujol J; González D; Fontcuberta J
Dig Dis Sci; 1995 Sep; 40(9):1883-9. PubMed ID: 7555437
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events.
Papa A; Danese S; Piccirillo N; Toriani-Terenzi C; Bartolozzi F; Piscaglia AC; Grillo A; Leone G; Gentiloni-Silveri N; Gasbarrini G; Gasbarrini A
Hepatogastroenterology; 2003; 50(49):132-5. PubMed ID: 12630008
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic alterations in inflammatory bowel disease: response to therapy.
Lake AM; Stauffer JQ; Stuart MJ
Am J Dig Dis; 1978 Oct; 23(10):897-902. PubMed ID: 717349
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of hypercoagulable disorders in inflammatory bowel disease.
Kohoutova D; Pecka M; Cihak M; Cyrany J; Maly J; Bures J
Scand J Gastroenterol; 2014 Mar; 49(3):287-94. PubMed ID: 24328909
[TBL] [Abstract][Full Text] [Related]
15. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements.
Vecchi M; Cattaneo M; de Franchis R; Mannucci PM
Int J Clin Lab Res; 1991; 21(2):165-70. PubMed ID: 1815761
[TBL] [Abstract][Full Text] [Related]
16. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease.
Alkim H; Ayaz S; Alkim C; Ulker A; Sahin B
Clin Appl Thromb Hemost; 2011; 17(6):600-4. PubMed ID: 21593018
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease.
Sonoda K; Ikeda S; Mizuta Y; Miyahara Y; Kohno S
J Gastroenterol; 2004 Oct; 39(10):948-54. PubMed ID: 15549447
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.
Jackson LM; O'Gorman PJ; O'Connell J; Cronin CC; Cotter KP; Shanahan F
QJM; 1997 Mar; 90(3):183-8. PubMed ID: 9093595
[TBL] [Abstract][Full Text] [Related]
19. Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis.
Seitz R; Leugner F; Katschinski M; Immel A; Kraus M; Egbring R; Göke B
Digestion; 1994; 55(6):361-7. PubMed ID: 7705548
[TBL] [Abstract][Full Text] [Related]
20. Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.
Vrij AA; Rijken J; van Wersch JW; Stockbrügger RW
Pathophysiol Haemost Thromb; 2003; 33(2):75-83. PubMed ID: 14624048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
